CN114642661A - 用于降低心血管风险的方法 - Google Patents

用于降低心血管风险的方法 Download PDF

Info

Publication number
CN114642661A
CN114642661A CN202210141115.7A CN202210141115A CN114642661A CN 114642661 A CN114642661 A CN 114642661A CN 202210141115 A CN202210141115 A CN 202210141115A CN 114642661 A CN114642661 A CN 114642661A
Authority
CN
China
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210141115.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·贝萨克
C·哈诺汀
R·C·波尔荻
W·J·萨西拉
G·G·施瓦兹
P·G·斯特格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN114642661A publication Critical patent/CN114642661A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210141115.7A 2014-03-17 2015-03-13 用于降低心血管风险的方法 Pending CN114642661A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293.1 2015-02-26
EP15305293 2015-02-26
CN201580024259.2A CN106794244A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580024259.2A Division CN106794244A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法

Publications (1)

Publication Number Publication Date
CN114642661A true CN114642661A (zh) 2022-06-21

Family

ID=52648962

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210141115.7A Pending CN114642661A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法
CN201580024259.2A Pending CN106794244A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法
CN202210141133.5A Pending CN114558129A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580024259.2A Pending CN106794244A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法
CN202210141133.5A Pending CN114558129A (zh) 2014-03-17 2015-03-13 用于降低心血管风险的方法

Country Status (14)

Country Link
US (2) US20150284473A1 (enExample)
EP (2) EP3119810B1 (enExample)
JP (3) JP2017509624A (enExample)
KR (3) KR20160132459A (enExample)
CN (3) CN114642661A (enExample)
AU (3) AU2015231713B2 (enExample)
CA (1) CA2942549A1 (enExample)
EA (1) EA039310B1 (enExample)
ES (1) ES2978990T3 (enExample)
HU (1) HUE066839T2 (enExample)
IL (1) IL304491A (enExample)
MX (1) MX380767B (enExample)
PL (1) PL3119810T3 (enExample)
WO (1) WO2015142668A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SI2443246T1 (en) 2009-06-15 2018-05-31 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CN110711248A (zh) 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
AU2014274844B2 (en) 2013-06-07 2019-11-28 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
AU2015289617B2 (en) * 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) * 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
EP3609532A1 (en) 2017-04-13 2020-02-19 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
CN113015543A (zh) * 2018-03-06 2021-06-22 赛诺菲生物技术公司 Pcsk9抑制剂用于降低心血管风险的用途
US20210155682A1 (en) * 2018-07-02 2021-05-27 Abcentra, Llc Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
MX2021001906A (es) * 2018-08-17 2021-04-28 Amarin Pharmaceuticals Ie Ltd Metodos para reducir la necesidad de revascularizacion arterial periferica en un sujeto tratado con estatinas.
HUE067138T2 (hu) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban
EP4470609A3 (en) 2019-01-18 2025-03-12 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
US20230045712A1 (en) * 2019-11-07 2023-02-09 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
IL323016A (en) * 2019-11-18 2025-10-01 Ad Pharmaceuticals Co Ltd Anti-pcsk9 antibody and its use
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN110711248A (zh) * 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Also Published As

Publication number Publication date
AU2024205254A1 (en) 2024-10-03
US20150284473A1 (en) 2015-10-08
US20220144969A1 (en) 2022-05-12
AU2015231713B2 (en) 2020-11-19
CA2942549A1 (en) 2015-09-24
CN106794244A (zh) 2017-05-31
JP2017509624A (ja) 2017-04-06
JP2022141868A (ja) 2022-09-29
KR20250006995A (ko) 2025-01-13
AU2015231713A1 (en) 2016-10-20
KR20160132459A (ko) 2016-11-18
IL304491A (en) 2023-09-01
AU2021201118A1 (en) 2021-03-11
EP4403213A3 (en) 2024-10-23
PL3119810T3 (pl) 2024-07-15
EP4403213A2 (en) 2024-07-24
MX380767B (es) 2025-03-12
EA039310B1 (ru) 2022-01-12
KR20220157516A (ko) 2022-11-29
JP2024147744A (ja) 2024-10-16
MX2016011975A (es) 2016-12-05
EA201691847A1 (ru) 2017-01-30
EP3119810A1 (en) 2017-01-25
EP3119810B1 (en) 2024-02-28
WO2015142668A1 (en) 2015-09-24
CN114558129A (zh) 2022-05-31
EP3119810C0 (en) 2024-02-28
ES2978990T3 (es) 2024-09-23
HUE066839T2 (hu) 2024-09-28

Similar Documents

Publication Publication Date Title
US20220144969A1 (en) Methods for reducing cardiovascular risk
RU2735521C2 (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
US20180296672A1 (en) Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy
CN107922507B (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
CN114306592A (zh) 用于治疗患有高胆固醇血症的高心血管风险患者的方法
TW201536315A (zh) 治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症之方法
CN105814085A (zh) Pcsk9抑制剂用于治疗高血脂症的用途
CN109069868B (zh) 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
AU2014348765A1 (en) Dosing regimens for use with PCSK9 inhibitors
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
CN115066272A (zh) Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1232890B (en) Methods for reducing cardiovascular risk
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов
HK40059806A (en) Dosing regimens for use with pcsk9 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination